Clinical Trial

Disease: Retinal Degeneration, (NCT03396042)

Disease info:

CEP290-related retinal degeneration describes types of inherited eye disorders caused by caused by the common intron 26 mutation in CEP290, including Leber congenital amaurosis.

Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. People with this disorder typically have severe visual impairment beginning in infancy.

 

Frequency:
Leber congenital amaurosis occurs in 2 to 3 per 100,000 newborns. It is one of the most common causes of blindness in children.
Official title:
Natural History Study of CEP290-Related Retinal Degeneration
Who:
Partners:
Locations:

United States, Florida

Bascom Palmer Eye Institute, Miami, Florida, United States, 33136
 

United States, Massachusetts

Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States, 02114
 

United States, Michigan

W.K. Kellogg Eye Center, Ann Arbor, Michigan, United States, 48105
 

United States, Oregon

Casey Eye Institute - OHSU, Portland, Oregon, United States, 97239
 

France

Universite Pierre et Marie Curie, Paris, France, 75252
 

Germany

Universitaetsklinikum Giessen and Marburg GmbH, Giessen, Germany, 35392
 

Netherlands

Radboud Universitair Medisch Centrum, Nijmegen, Gelderland, Netherlands, 6525

Study start:
Dec. 17, 2017
Enrollment:
26 participants
Gene editing method:
N/A
Type of edit:
N/A
Gene:
CEP290
Delivery method:
N/A
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Completed

Description

The purpose of the study is to describe the natural history of CEP290-related retinal degeneration caused by a compound heterozygous or homozygous intron 26 c.2991+1655A>G mutation and to better understand the best assessments for evaluation of patients with this condition in a future interventional trial. Patients meeting the entry criteria will be enrolled in the study. Visits will occur at Screening, Baseline, and Months 3, 6, and 12, for a total duration of 1 year.

Last updated: Sep. 1, 2024
close
Search CRISPR Medicine